CDC42 and breast cancer: Targeting this Reelin-LRP8-CDC42 axis with MEN 10207, a neurokinin-2 receptor antagonist, inhibited BC cell migration and reduced BM in zebrafish and mouse models, offering a promising therapeutic strategy.